ITGAE and neoplasm: The tumor lesions of mice receiving rlipoE7m-MoGM therapy showed a reduced number of TAMs, whereas the numbers of CD103+ DCs and CD11b+ DCs remained unchanged before tumor regression, suggesting that the marked reduction in the TAM population was not an artifact of tumor shrinkage (figure 4B).